BHC
Get informed when a big investor buys or sells
+ FollowUndervalued by 179.9% based on the discounted cash flow analysis.
| Market cap | $2.00 Billion |
|---|---|
| Enterprise Value | $21.50 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.43 |
| Beta | 0.42 |
| Outstanding Shares | 372,800,000 |
| P/E Ratio | -1.68 |
|---|---|
| PEG | -0.07 |
| Price to Sales | 0.22 |
| Price to Book Ratio | -1.65 |
| Enterprise Value to Revenue | 2.5 |
| Enterprise Value to EBIT | 10.16 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0.97 |
| Debt to Equity | -10.1 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9200▼ 146.10% |
|---|---|
| Total Calls | 1,883,400▲ 67.53% |
| Total Puts | 3,616,100▼ 4.86% |
Holdings and activity of institutional investors.
| Ownership % | 62.79%▼ 0.73% |
|---|---|
| Total Invested | $1.26B▼ 23.02% |
| Investors Holding | 245▼ 8.00% |
No data
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter ...